Evidence map›Paper›PMID 37954002›Full record

ArticleThe Lancet regional health. Europe2023

Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study.

Lourdes Mateu, Cristian Tebe, Cora Loste, José Ramón Santos, Gemma Lladós, Cristina López, Sergio España-Cueto, Ruth Toledo, Marta Font, Anna Chamorro and 16 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Evolutionary Predictors of Post-COVID Syndrome.Journal of clinical medicine · 2026
    Article
  5. Review
  6. Review
  7. Cellular Metabolic Signatures of Long COVID-19.Infectious disease reports · 2026
    Article
  8. Article
  9. Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 2 countries.

Lourdes MateuDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Cristian TebeBiostatistics Unit, Hospital Germans Trias i Pujol, Institut de Recerca Germans Trias i Pujol, Can Ruti Campus, Badalona, Catalonia, Spain.
Cora LosteDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
José Ramón SantosDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Gemma LladósDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Cristina LópezDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Sergio España-CuetoDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Ruth ToledoDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Marta FontDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Anna ChamorroDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Francisco Muñoz-LópezIrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.
Maria NevotIrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.
Nuria VallejoCardiology Department, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Albert TeisCardiology Department, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Jordi PuigDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Carmina R FumazDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
José A Muñoz-MorenoDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Anna PratsDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Carla Estany-QueraDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Roser Coll-FernándezREICOP, Spain.
Cristina HerreroDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Patricia CasaresDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Ana GarciaDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Bonaventura ClotetDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Roger ParedesDepartment of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.
Marta MassanellaREICOP, Spain.
Fundació ACE · ESHospital Universitari Germans Trias i Pujol · ESUniversitat de Vic - Universitat Central de Catalunya · ESIrsiCaixa · ESInstituto de Salud Carlos III · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: At least 5-10% of subjects surviving COVID-19 develop the post-COVID-19 condition (PCC) or "Long COVID". The clinical presentation of PCC is heterogeneous, its pathogenesis is being deciphered, and objective, validated biomarkers are lacking. It is unknown if PCC is a single entity or a heterogeneous syndrome with overlapping pathophysiological basis. The large US RECOVER study identified four clusters of subjects with PCC according to their presenting symptoms. However, the long-term clinical implications of PCC remain unknown. Methods: We conducted a 2-year prospective cohort study of subjects surviving COVID-19, including individuals fulfilling the WHO PCC definition and subjects with full clinical recovery. We systematically collected post-COVID-19 symptoms using prespecified questionnaires and performed additional diagnostic imaging tests when needed. Factors associated with PCC were identified and modelled using logistic regression. Unsupervised clustering analysis was used to group subjects with PCC according to their presenting symptoms. Factors associated with PCC recovery were modelled using a direct acyclic graph approach. Findings: The study included 548 individuals, 341 with PCC, followed for a median of 23 months (IQR 16.5-23.5), and 207 subjects fully recovered. In the model with the best fit, subjects who were male and had tertiary studies were less likely to develop PCC, whereas a history of headache, or presence of tachycardia, fatigue, neurocognitive and neurosensitive complaints and dyspnea at COVID-19 diagnosis predicted the development of PCC. The cluster analysis revealed the presence of three symptom clusters with an additive number of symptoms. Only 26 subjects (7.6%) recovered from PCC during follow-up; almost all of them (n = 24) belonged to the less symptomatic cluster A, dominated mainly by fatigue. Recovery from PCC was more likely in subjects who were male, required ICU admission, or had cardiovascular comorbidities, hyporexia and/or smell/taste alterations during acute COVID-19. Subjects presenting with muscle pain, impaired attention, dyspnea, or tachycardia, conversely, were less likely to recover from PCC. Interpretation: Preexisting medical and socioeconomic factors, as well as acute COVID-19 symptoms, are associated with the development of and recovery from the PCC. Recovery is extremely rare during the first 2 years, posing a major challenge to healthcare systems. Funding: Fundació Lluita contra les Infeccions.

Indexed as

COVID-19Long COVID-19Post-COVID-19 condition

Identifiers

PMID37954002
PMCPMC10636281
OpenAlexW4386459943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.